BNET Industries
- Private
- US
Dow Jones Description
Invitrogen is committed to being the leading provider of novel fluorescent reagents and detection solutions that advance scientific and biomedical research worldwide. Supplying superior Molecular Probes products and services, together with striving for customer and employee satisfaction, will be the driving forces of our organization.
Senior Vice President
Ben BulkleyPeer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
invitrogen corp. and robots - All News and Analysis
Holiday season spurs strong November for stock indexes
Crude oil prices continue to play a significant role in driving stock market fluctuations. November saw oil prices fall from their record high of $55.67 per barrel last month to as low as $46.87 per barrel on November 15. Oil prices shot back up to over $50 per barrel due...
Roller coaster month ends on positive note for IBO indexes
A barrage of negative macroeconomic events early in October sent all three major US Stock Indexes tumbling, with the Dow Jones Industrial Average reaching an intraday low for the year at 9,708.40. The Labor Department's figures for September job growth came in much weaker than expected, with only 96,000 jobs...
Laboratory Instrument companies outpace US Indexes
Cautious optimism remains the theme for the US economy in general and for the three major US stock indexes as the summer comes to an end. During September, the Federal Reserve raised interest rates another quarter point to 1.75% as expected, noting that the economy is regaining some momentum after...
Economic concerns slow growth of IBO indexes in August
August proved to be a stagnant period for all major US stock indexes, with concerns over oil prices and terror threats. Investors were cautious at the beginning of the month when the Department of Homeland Security issued a warning about possible terror attacks on key US financial institutions. Stocks continued...
Instrumentation stocks continue to post gains
During November, all four IBO indices experienced very moderate gains, while the three major US stock indices remained relatively flat compared to the previous month. Early in the month, blue-chip stocks hit 17-month highs due to strong manufacturing data and a slight decline in the unemployment rate to 6.0%. However,...
Instrument stocks' performances mixed in June
The final month of the first half of 2003 proved to be mediocre at best for the three major US stock indices, which all experienced minimal growth between 1% and 2%. Consumer spending remained somewhat sluggish, leaving the overall economy at a standstill. On the 26th of June, the Federal...
Prospects brighten for instrument equities
The three major US indices made considerable improvements over the month of April due to a number of factors. Investors proved to be fairly optimistic now that the war with Iraq appears to be over and tensions with North Korea are improving. The end of the war also caused crude...
Three IBO stock indices post losses for January
For the most part, the economic news in January was fairly positive. The government reported that in the last three months of 2001, the economy grew at a rate of 0.2% as compared to the third quarter decline of 1.3%. After the end of the first month of 2002,...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Ben Bulkley | Senior Vice President |
| David U'Prichard | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald W Grimm | Board Member |
| Raymond V. Dittamore | Board of Directors |
| W. Ann Reynolds PhD | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Invitrogen Corporation | Senior Vice President | Current |
| UCSD-CONNECT | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Venture Partner | Current |
| Red Abbey, LLC | Senior Advisor and Venture Partner | Current |
| University of Glasgow | Honorary Professor | Current |
| Red Abbey, LLC | Advisor | Current |
| Northwestern University | Associate Professor | Current |
| Glasgow University | Honorary Professor | Current |
| Genematrix, Inc. | Board Director | Current |
| Exsar Corporation | Board Director | Current |
| Guilford Pharmaceuticals, Inc. | Director | Current |
| Invitrogen Corporation | Director | Current |
| Cyclacel Limited | Board of Directors | Current |
| GlaxoSmithKline Plc | President | Former |
| SmithKline Beecham Corporation | President of Research and Development | Former |
| Druid Consulting | President | Former |
| Apax Partners Ltd. | Venture Partner | Former |
| Northwestern University School of Medicine | Associate Professor of Pharmacology and Neurobiology | Former |
| Biotechnology Industry Organization | member | Former |
| GlaxoSmithKline Plc | Chairman of Research and Development | Former |
| SmithKline Beecham Corporation | Chairman of R&D | Former |
| Biotechnology Industry Organization | Board Member | Former |
| University of Kansas | Ph.D. in Pharmacology | Former |
| University of Kansas | MS | Former |
| University of Glasgow | B.Sc. in Pharmacology | Former |
| Organization | Position | Status |
|---|---|---|
| Oligoperfect | Founder, Chairman and President, Strategic Design | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Founder, Chairman and President, Strategic Design | Current |
| Resgen Inc. | Founder, Chairman and President, Strategic Design | Current |
| Emiliem, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Hamilton BioVentures | President | Current |
| Molecular Probes | Founder, Chairman and President, Strategic Design | Current |
| Biolayer Corporation Limited | Founder, Chairman and President, Strategic Design | Current |
| Strategic Design | President | Current |
| IDEXX Laboratories, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Seqanswers | Founder, Chairman and President, Strategic Design | Current |
| Microseq | Founder, Chairman and President, Strategic Design | Current |
| Industry Ventures | Founder, Chairman and President, Strategic Design | Current |
| Olink | Founder, Chairman and President, Strategic Design | Current |
| Ionsource, LLC | Founder, Chairman and President, Strategic Design | Current |
| Bioreliance Corporation | Founder, Chairman and President | Current |
| Aegis Therapeutics, LLC | Executive Chairman | Current |
| Strategic Design | Chairman | Current |
| San Diego Regional Chamber of Commerce | Vice Chair | Current |
| Cellzdirect, Inc. | Board of Directors | Current |
| High Throughput Genomics, Inc. | Board of Directors | Current |
| Hamilton BioVentures | Director | Current |
| Intec Telecommunications | Board Member | Current |
| Invitrogen Corporation | Board Member | Current |
| University of Pittsburgh School of Pharmacy | Board Member | Current |
| Angstrom Pharmaceuticals, Inc. | Board of Directors | Current |
| Multiple Peptide Systems Inc | Board of Directors | Current |
| Scripps Clinic | Board Member | Current |
| Hybritech, Inc. | CEO | Former |
| Dura Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Biosource International, Inc. | Founder, Chairman and President, Strategic Design | Former |
| Hybritech, Inc. | President | Former |
| Copenhagen Capacity | Managing Director | Former |
| Hybritech, Inc. | Director of West Coast Pharmaceutical Sales | Former |
| Eli Lilly and Company | Director of Pharmaceutical Market Research | Former |
| Eli Lilly and Company | management positions | Former |
| U.S. Army | Officer | Former |
| Xcel Pharmaceuticals, Inc. | Former | |
| Verus Pharmaceuticals | Former | |
| Cadence Pharmaceuticals, Inc. | Former | |
| Hybritech, Inc. | Chairman | Former |
| Hybritech | Chairman | Former |
| Biovail Corporation | Chairman | Former |
| Pharmaceutical Market Research | Director | Former |
| Roundtable Inc. | Board of Directors | Former |
| Bioreliance Corporation | Director | Former |
| Somaxon Pharmaceuticals, Inc. | Board of Directors | Former |
| California Healthcare Institute, Inc. | Board of Directors | Former |
| University of Pittsburgh | M.B.A. | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | M.B.A. | Former |
| Baldwin-Wallace College | Master's Degree In Business Administration | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | B.S. In Pharmacy | Former |
| University of Pittsburgh | B.S. In Pharmacy | Former |
Raymond V. Dittamore has served as a Director of the Company since December 2002. Mr. Dittamore is a retired audit partner of Ernst & Young LLP, an international accounting firm. Mr. Dittamore retired in 2001 after 35 years of service with that firm, including 14 years as the managing partner of the firms San Diego office. Mr. Dittamore is also a director of Invitrogen Corporation, Gen-Probe Incorporated, and Digirad Corporation. Mr. Dittamore received a B.S. degree from San Diego State University.
| Organization | Position | Status |
|---|---|---|
| QUALCOMM Incorporated | Board of Directors | Current |
| Molecular Probes | Director | Current |
| Invitrogen Corporation | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Biolayer Corporation Limited | Director | Current |
| Ionsource, LLC | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Applied Molecular Evolution, Inc. | Director | Current |
| Ernst & Young | partner | Former |
| Ernst & Young | collaborative editor | Former |
| Digirad Corporation | Board of Directors | Former |
| San Diego State University | B.S. | Former |
| QUALCOMM Incorporated | member | Former |
W. Ann Reynolds, 71, formerly President and Professor of Biology at The University of Alabama at Birmingham, located in Birmingham, Alabama, until 2002. Director since 2006; formerly a Director of OCD since 1993. A graduate of Kansas State Teachers College and the University of Iowa, where she earned a Ph.D. degree, Dr. Reynolds previously served as Chancellor of the City University of New York and as Chancellor of the California State University System. In prior years, she was Provost of the Ohio State University and Professor of Anatomy and Vice Chancellor for Research at the University of Illinois at the Medical Center. Dr. Reynolds is a director of Humana, Inc., Abbott Laboratories, Invitrogen Corporation, and the News-Gazette, Champaign, Illinois.
| Organization | Position | Status |
|---|---|---|
| News Gazette Inc. | Director | Current |
| Humana Inc. | Board of Directors | Current |
| Abbott Laboratories | Board of Directors | Current |
| Owens Corning | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Business-Higher Education Forum | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Olink | Board of Directors | Current |
| KMG America Corporation | Member of The Board of The Champaign, Urbana News Gazette | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Resgen Inc. | Board of Directors | Current |
| Maytag Corporation | Board of Directors | Current |
| Ionsource, LLC | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Abms Member | Board of Directors | Current |
| Invitrogen Corporation | Board of Directors | Current |
| The University of Alabama at Birmingham | President | Former |
| University of Illinois | Professor | Former |
| University of Illinois College of Medicine | Research Professor | Former |
| Emporia State University | M.S. | Former |
| Emporia State University | Bachelors Degree In Biology | Former |
Industry Transcripts by Seeking Alpha
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes

